BLOG > Publications & Citations > Inhibition of pathogenic tau signaling by novel small molecules
Authors: Nowar R et al.
Source: Front. Pharmacol. 17:1829420.
We are delighted to share insights from a recent study entitled "Inhibition of pathogenic tau signaling via blocking of the phosphatase-activating domain by novel small molecules" published in Frontiers in Pharmacology by Raghad Nowar et al.
They identified a series of novel small-molecule inhibitors that target a specific toxic region of the tau protein known as the phosphatase-activating domain (PAD). By blocking this domain, these compounds successfully prevented the pathological signaling that leads to neurodegeneration, effectively rescuing neurons and restoring axonal growth in cellular models of tauopathy.
Congratulations to all authors for this great article.
NeuroMag was used to transfect primary cortical neurons with tau DNA constructs. This efficient delivery allowed the team to perform nanoBRET target engagement assays and evaluate the neuroprotective efficacy of their candidate molecules in highly relevant neuronal environment.
Related publications
Human corticospinal connectoid model for post-injury axon regrowth
ITCH regulates Golgi integrity and proteotoxicity in neurodegeneration
